Stock Track | Verona Pharma Soars 5.19% in Pre-market Trading on Analyst's Buy Rating for COPD Drug

Stock Track18:36

Verona Pharma plc (VRNA) witnessed a significant pre-market surge of 5.19% on Friday, following a new Buy rating from Roth MKM analyst Boobalan Pachaiyappan for the company's Ohtuvayre drug, a potential treatment for chronic obstructive pulmonary disease (COPD).

Pachaiyappan's Buy recommendation stems from his belief that Ohtuvayre represents a unique solution in the COPD market, citing its potential to address a significant unmet need and drive revenue growth for Verona Pharma. The analyst's positive outlook is underpinned by the substantial market opportunity for effective COPD treatments and the promising clinical data supporting Ohtuvayre's efficacy and safety profile.

The pre-market rally in Verona Pharma's stock reflects investors' optimism surrounding Ohtuvayre's prospects, as the company continues to advance its development and seeks regulatory approvals. With a favorable analyst rating and the potential for a successful COPD therapy, Verona Pharma has garnered increased attention from the investment community.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1178664111?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-10 18:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1178664111","market":"us","top_or_hot":-1,"title":"Stock Track | Verona Pharma Soars 5.19% in Pre-market Trading on Analyst's Buy Rating for COPD Drug","media":"Stock Track","content":"<p>Verona Pharma plc (VRNA) witnessed a significant pre-market surge of 5.19% on Friday, following a new Buy rating from Roth MKM analyst Boobalan Pachaiyappan for the company's Ohtuvayre drug, a potential treatment for chronic obstructive pulmonary disease (COPD).</p>\n\n<p>Pachaiyappan's Buy recommendation stems from his belief that Ohtuvayre represents a unique solution in the COPD market, citing its potential to address a significant unmet need and drive revenue growth for Verona Pharma. The analyst's positive outlook is underpinned by the substantial market opportunity for effective COPD treatments and the promising clinical data supporting Ohtuvayre's efficacy and safety profile.</p>\n\n<p>The pre-market rally in Verona Pharma's stock reflects investors' optimism surrounding Ohtuvayre's prospects, as the company continues to advance its development and seeks regulatory approvals. With a favorable analyst rating and the potential for a successful COPD therapy, Verona Pharma has garnered increased attention from the investment community.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Verona Pharma Soars 5.19% in Pre-market Trading on Analyst's Buy Rating for COPD Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Verona Pharma Soars 5.19% in Pre-market Trading on Analyst's Buy Rating for COPD Drug\n</h2>\n\n<h4 class=\"meta\">\n\n2025-01-10 18:36 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Verona Pharma plc (VRNA) witnessed a significant pre-market surge of 5.19% on Friday, following a new Buy rating from Roth MKM analyst Boobalan Pachaiyappan for the company's Ohtuvayre drug, a ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"","article_id":"1178664111","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1178664111","pubTimestamp":1736505376,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Verona Pharma plc  witnessed a significant pre-market surge of 5.19% on Friday, following a new Buy rating from Roth MKM analyst Boobalan Pachaiyappan for the company's Ohtuvayre drug, a potential treatment for chronic obstructive pulmonary disease .Pachaiyappan's Buy recommendation stems from his belief that Ohtuvayre represents a unique solution in the COPD market, citing its potential to address a significant unmet need and drive revenue growth for Verona Pharma. The analyst's positive outloo","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"分析师对COPD药物给予买入评级，Verona Pharma股价在盘前交易中飙升5.19%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VRNA":1},"content_text":"Verona Pharma plc (VRNA) witnessed a significant pre-market surge of 5.19% on Friday, following a new Buy rating from Roth MKM analyst Boobalan Pachaiyappan for the company's Ohtuvayre drug, a potential treatment for chronic obstructive pulmonary disease (COPD).\nPachaiyappan's Buy recommendation stems from his belief that Ohtuvayre represents a unique solution in the COPD market, citing its potential to address a significant unmet need and drive revenue growth for Verona Pharma. The analyst's positive outlook is underpinned by the substantial market opportunity for effective COPD treatments and the promising clinical data supporting Ohtuvayre's efficacy and safety profile.\nThe pre-market rally in Verona Pharma's stock reflects investors' optimism surrounding Ohtuvayre's prospects, as the company continues to advance its development and seeks regulatory approvals. With a favorable analyst rating and the potential for a successful COPD therapy, Verona Pharma has garnered increased attention from the investment community.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1178664111"}